Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-centre, multinational, open-label, active-controlled, two armed, parallel-group, randomised trial in subjects with type 2 diabetes
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs Insulin aspart (Primary) ; Semaglutide (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN 11
- Sponsors Novo Nordisk
- 04 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2019 Planned End Date changed from 13 Nov 2020 to 22 Feb 2021.
- 07 Oct 2018 Status changed from not yet recruiting to recruiting.